Novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Trial Identifier: D7986C00001
Sponsor: AstraZeneca
Start Date: January 2023
Primary Completion Date: July 2026
Study Completion Date: September 2027
Condition: Gastric Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Hangzhou, CN, 310020
CN Hangzhou, CN, 310003
CN Harbin, CN, 150081
CN Hefei, CN, 230031
CN Kunming, CN, 650118
CN Wuhan, CN, 430079
CN Yinchuan, CN, 750004
CN Zhengzhou, CN, 450052
ES Barcelona, ES, 08035
ES Elche(Alicante), ES, 03202
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28040
ES Madrid, ES, 28007
ES Santander, ES, 39008
GB Leeds, GB, LS9 7TF
GB London, GB, EC1M 6BQ
GB Oxford, GB, OX3 7LE
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 227-8577
JP Sunto-gun, JP, 411-8777
KR seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 03080
TW Hsinchu, TW, 300
TW Kaohsiung, TW, 80756
TW Taichung, TW, 404
TW Tainan City, TW, 70403
TW Taipei, TW, 11259
TW Taipei, TW, 10002
TW Taoyuan, TW, 333
US, CA Los Angeles, CA, US, 90017
US, LA Baton Rouge, LA, US, 70817
US, MI Grand Rapids, MI, US, 49503
US, NY New York, NY, US, 10065